Interactions between herbs and conventional drugs: Overview of the clinical data

Medical Principles and Practice

Volumn 21, Issue 5, 2012, Pages 404-428

  Izzo, Angelo A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Complementary medicine; Cytochrome P; Dietary supplements; Drug interaction; Herbal medicine; P glycoprotein; Safety of herbal products; St. John's wort; Traditional Chinese medicine

Indexed keywords

ALOE VERA EXTRACT; ANGELICA SINENSIS EXTRACT; ATAZANAVIR; CHAMOMILE; CHLORPROPAMIDE; CHLORZOXAZONE; CIMICIFUGA RACEMOSA EXTRACT; CRANBERRY EXTRACT; CYCLOSPORIN; DEBRISOQUINE; DEXTROMETHORPHAN; DIGOXIN; ECHINACEA EXTRACT; EFAVIRENZ; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; FLUINDIONE; GARLIC EXTRACT; GARLIPURE; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; OMEPRAZOLE; PARACETAMOL; RITONAVIR; SALVIA MILTIORRHIZA EXTRACT; SAQUINAVIR; SEVOFLURANE; TOLBUTAMIDE; UNCARIA TOMENTOSA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMENORRHEA; ANTICOAGULATION; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTERIOSCLEROSIS; BLEEDING; BRAIN ISCHEMIA; COGNITIVE DEFECT; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSMENORRHEA; GASTROINTESTINAL DISEASE; HEART INFARCTION; HERB DRUG INTERACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSTIMULATION; INFECTION; INFLAMMATORY DISEASE; MAXIMUM PLASMA CONCENTRATION; MENOPAUSAL SYNDROME; NAUSEA AND VOMITING; PATIENT COUNSELING; POSTOPERATIVE NAUSEA AND VOMITING; PRESCRIPTION; RESPIRATORY TRACT INFECTION; RETROPERITONEAL HEMORRHAGE; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; URINARY TRACT INFECTION;

AGE FACTORS; CONTINENTAL POPULATION GROUPS; GENOTYPE; HERB-DRUG INTERACTIONS; HUMANS; PATIENT EDUCATION AS TOPIC; PHARMACEUTICAL PREPARATIONS; PHYTOTHERAPY; PLANT PREPARATIONS; SEX FACTORS;

EID: 84865010199     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000334488     Document Type: Review

References (249)

1. World Health Organisation (WHO): General guidelines for methodologies on research and evaluation of traditional medicine. http://www.who.int/en/.
2. Ernst E, Pittler MH, Wider B: The Desktop Guide to Complementary and Alternative Medicine. An Evidence-Based Approach. Philadelphia, Mosby Elsevier, 2006.
3. Ernst E, Pittler MH, Wider B, Boddy K: Oxford Handbook of Complementary Medicine. Oxford, Oxford University Press, 2008.
4. Capasso F, Gaginella TS, Grandolini G, Izzo AA: Phytotherapy. A Quick Reference to Herbal Medicine. Berlin, Springer-Verlag, 2003.
5. Blumenthal M: The Complete German Commission E Monographs. Austin, American Botanical Council, 1998.
6. Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, Xue CC, Herington A: Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007; 12:664-673.
7. Kennedy DA, Seely D: Clinically based evidence of drug-herb interactions: a systematic review. Expert Opin Drug Saf 2010; 9: 79-124.
8. Izzo AA, Ernst E: Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69:1777-1798.
9. Colalto C: Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol Res 2010; 62: 207-227.
10. Zhou SF: Drugs behave as substrates, inhibitors and inducers of human cytochrome P4503A4. Curr Drug Metab 2008; 9: 310-322.
11. Zhang W, Han Y, Lim SL, Lim LY: Dietary regulation of P-gp function and expression. Expert Opin Drug Metab Toxicol 2009; 5: 789-801.
12. Tomlinson B, Hu M, Lee VW: In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? Mol Nutr Food Res 2008; 52: 799-809.
13. Lee A, Chui PT, Aun CS, Gin T, Lau AS: Possible interaction between sevoflurane and Aloe vera. Ann Pharmacother 2004; 38:1651-1654.
14. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A: In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P4501A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77:415-426.
15. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry W B, Breen P, Carrier DJ, Cheboyina S: Assessing the clinical significance of botanical supplementation on human cytochrome P4503A activity: comparison of a milk thistle and black co-hosh product to rifampin and clarithromy-cin. J Clin Pharmacol 2006; 46:201-213.
16. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S: Effect of milk thistle (Silybum marianum) and black co-hosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2006; 34: 69-74.
17. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK: Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St John's wort, and Echinacea. Mol Nutr Food Res 2008; 52:755-763.
18. Wanwimolruk S, Wong K, Wanwimolruk P: Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4. Drug Me-tabol Drug Interact 2009; 24:17-35.
19. López Galera RM, Ribera Pascuet E, Esteban Mur JI, Montoro Ronsano JB, Juárez Gimé-nez JC: Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir. Eur J Clin Pharmacol 2008; 64: 1235-1236.
20. No Author listed: Herb-drug interactions: reported vs potential effects; in Rotblatt M, Ziment I (eds): Ev idence-Based Herba l Medicine. Philadelphia, Hanley & Belfus, 2002, pp 45-55.
21. Segal R, Pilote L: Warfarin interaction with Matricaria chamomilla. CMAJ 2006; 174: 1281-1282.
22. MHRA/CSM: Interaction between warfarin and cranberry juice. New advice. Curr Probl Pharmacovigil 2003;30: 10.
23. Aston JL, Lodolce AE, Shapiro NL: Interaction between warfarin and cranberry juice. Pharmacot herapy 2006; 26: 1314-1319.
24. Pham DQ, Pham AQ: Interaction potential between cranberry juice and warfarin. Am J Health Syst Pharm 2007; 64:490-494.
25. Mergenhagen KA, Sherman O: Elevated International Normalized Ratio after concurrent ingestion of cranberry sauce and warfarin. Am J Health Syst Pharm 2008; 65:2113-2116.
26. Griffiths AP, Beddall A, Pegler S: Fatal hae-mopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin. J R Soc Promot Health 2008; 128:324-326.
27. Suvarna R, Pirmohamed M, Henderson L: Possible interaction between warfarin and cranberry juice. BMJ 2003; 327:1454.
28. Grant P: Warfarin and cranberry juice: an interaction? J Heart Valve Dis 2004; 13: 25-56.
29. Paeng CH, Sprague M, Jackevicius CA: Interaction between warfarin and cranberry juice. Clin Ther 2007; 29:1730-1735.
30. Rindone JP, Murphy TW: Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. Am J Ther 2006; 13: 283-284.
31. Paeng CH, Sprague M, Jackevicius CA: Interaction between warfarin and cranberry juice. Clin Ther 2007; 29:1730-1735.
32. Zikria J, Goldman R, Ansell J: Cranberry juice and warfarin: when bad publicity trumps science. Am J Med 2010; 123:384-392.
33. Mohammed Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ: Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008; 154:1691-1700.
34. Li Z, Seeram NP, Carpenter CL, Thames G, Minutti C, Bowerman S: Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 2006; 106:2057-2061.
35. Ansell J, McDonough M, Zhao Y, Harmatz JS, Greenblatt DJ: The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. J Clin Pharmacol 2009; 49:824-830.
36. Lilja JJ, Backman JT, Neuvonen PJ: Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizani-dine, and midazolam-probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther 2007; 81: 833-839.
37. Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA: Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 2006; 79: 125-133.
38. Ushijima K, Tsuruoka S, Tsuda H, Hasegawa G, Obi Y, Kaneda T, Takahashi M, Maekawa T, Sasaki T, Koshimizu TA, Fujimura A: Cranberry juice suppressed the diclofenac metabolism by human liver microsomes, but not in healthy human subjects. Br J Clin Pharmacol 2009; 68: 194-200.
39. Pham DQ, Pham AQ: Interaction potential between cranberry juice and warfarin. Am J Health Syst Pharm 2007; 64:490-494.
40. Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP: Pomelo juice, but not cranberry juice, affects the pharma-cokinetics of cyclosporine in humans. Clin Pharmacol Ther 2006; 79: 255-262.
41. Chan TY: Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharma-cother 2001; 35: 501-504.
42. Izzat MB, Yim AP, El-Zufari MH: A taste of Chinese medicine. Ann Thorac Surg 1998; 66:941-942.
43. Tam LS, Chan TY, Leung WK, Critchley JA: Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil. Aust NZ J Med 1995; 25:258.
44. Yu CM, Chan JC, Sanderson JE: Chinese herbs and warfarin potentiation by danshen. J Intern Med 1997; 25:337-339.
45. Qiu F, Wang G, Zhang R, Sun J, Jiang J, Ma Y: Effect of danshen extract on the activity of CYP3A4 in healthy volunteers. Br J Clin Pharmacol 2010; 69:656-662.
46. Ellis GR, Stephens MR: Untitled (photograph a nd brief case repor t). BMJ 1999; 19: 650.
47. Page RL, Lawrence JD: Potentiation of warfarin by dong quai. Pharmacotherapy 1999; 319: 870-876.
48. Gurley BJ, Swain A, Williams DK, Barone G, Battu SK: Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St John's wort, Echinacea, clarithromycin, and ri-fampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008; 52:772-779.
49. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A: In vivo assessment of botanical supplementation on human cyto-chrome P450 phenotypes: Citrus auran-tium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol 2004; 76: 428-440.
50. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD: The effect of echinacea (Echi-nacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89-100.
51. Moltó J, Valle M, Miranda C, Cedeño S, Ne-gredo E, Barbanoj MJ, Clotet B: Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients. Antimicrob Agents Chemother 2011; 55:326-330.
52. Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS: Siberian ginseng (Eleu-theroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 2003; 31: 519-522.
53. McRae S: Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ 1996; 155:293-295.
54. Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL: Effects of garlic (Allium sativum L.) supplementation on cy-tochrome P4502D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74: 170-177.
55. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY: Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlicoil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005; 22: 525-539.
56. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY: Cyto-chrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72:276-287.
57. Jabbari A, Argani H, Ghorbanihaghjo A, Mahdavi R: Comparison between swallowing and chewing of garlic on levels of serum lipids, cyclosporine, creatinine and lipid per-oxidation in renal transplant recipients. Lip-ids Health Dis 2005; 4:11.
58. Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM: Inf luence of garlic (Allium sativ um) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12: 4636-4640.
59. Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K: Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010; 41: 729-735.
60. Sunter WH: Warfarin and garlic. Pharm J 1991; 246: 772.
61. Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y: Aged garlic extract may be safe for patients on warfarin t herapy. J Nutr 2006; 136: 793S-795S.
62. Abdul MMI, Jiang X, Williams KM, Day RO, Roufogalis BD, Liauw WS, Xu H, McLachlan AJ: Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008; 154:1691-1700.
63. Pathak A, Léger P, Bagheri H, Senard JM, Boccalon H, Montastruc JL: Garlic interaction with fluindione: a case report. Therapie 2003; 58: 380-381.
64. Piscitelli SC, Burstein AH, Welden N, Gal-licano KD, Falloon J: The effect of garlic supplements on the pharmacokinetics of sa-quinavir. Clin Infect Dis 2002; 34: 234-238.
65. Berginc K, Trdan T, Trontelj J, Kristl A: HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. Biopharm Drug Dispos 2010; 31: 495-505.
66. Gallicano K, Foster B, Choudhri S: Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacoki-netics in healthy volunteers. Br J Clin Pharmacol 2003; 55: 199-202.
67. Laroche M, Choudhuri S, Gallicano K, Foster B: Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can J Infect Dis 1998; 9: 471P.
68. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL: The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Bio-markers Prev 1994; 3:155-160.
69. Aslam M, Stockley IH: Interaction between curry ingredient (karela) and drug (chlor-propamide). Lancet 1979;i:607.
70. Krüth P, Brosi E, Fux R, Mörike K, Gleiter CH: Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother 2004; 38: 257-260.
71. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ: Effect of ginkgo and ginger on the pharmacokinetics and pharmacody-namics of warfarin in healthy subjects. Br J Clin Pha rmacol 2005; 59: 425-432.
72. Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD: Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-4502D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003; 23: 576-581.
73. Mohutsky MA, Anderson GD, Miller JW, Elmer GW: Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 2006; 13: 24-31.
74. Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW: Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003; 10: 247-251.
75. Robertson SM, Davey RT, Voell J, Formentini E, Alfaro R M, Penzak SR: Effect of Gink-go biloba extract on lopinavir, midazo-lam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008; 24: 591-599.
76. Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Har-matz JS, Avula B, Khan IA, Goldman P: Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 2006; 46:214-221.
77. Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S: Effects of Ginkgo biloba extract on pharmacokinetics and pharmaco-dynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46:1290-1298.
78. Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nakagawa M, Matsumoto T, Tagagi K, Takara K, Ohkuni T, Yokoyama T, Kuroda K: Studies on interactions between functional foods or dietary supplements and medicines. 1 V. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004; 27:2006-2009.
79. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS: Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-850.
80. Zuo XC, Zhang BK, Jia SJ, Liu SK, Zhou LY, Li J, Zhang J, Dai LL, Chen BM, Yang GP, Yuan H: Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 2010; 66: 503-509.
81. Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, Li Q, Lei HP, Jiang F, Hu DL, Huang YF, Zhou HH: Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother 2009; 43:944-949.
82. Fan L, Mao XQ, Tao GY, Wang G, Jiang F, Chen Y, Li Q, Zhang W, Lei HP, Hu DL, Huang YF, Wang D, Zhou HH: Effect of Schisandra chinensis extract and Ginkgo bi-loba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 2009; 39:249-254.
83. Bone KM: Potential interaction of Ginkgo bi-loba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res 2008; 52:764-771.
84. Aruna D, Naidu MU: Pharmacodynamic interaction studies of Ginkgo biloba with cilo-stazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007; 63:333-338.
85. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ: Effect of ginkgo and ginger on the pharmacokinetics and pharmacody-namics of warfarin in healthy subjects. Br J Clin Pharmacol 2005; 59: 425-432.
86. Engelsen J, Nielsen JD, Winther K: Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin-treated outpatients. A randomised, double blind, placebo-crossover tria l. Thromb Hae-most 2002; 87:1075-1076.
87. Rosenblatt M, Mindel J: Spontaneous hy-phema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336:1108.
88. Matthews MK Jr: Association of Ginkgo bi-loba with intracerebral hemorrhage. Neurology 1998; 50:1933-1934.
89. Meisel C, Johne A, Roots I: Fatal intracere-bral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 2003; 167: 367.
90. Lin YY, Chu SJ, Tsai SH: Association between priapism and concurrent use of ris-peridone and Ginkgo biloba. Mayo Clin Proc 2007; 82: 1289-1290.
91. Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB: Coma in a patient with Alzheimer's disease taking low dose trazodone and Gingko biloba. J Neurol Neurosurg Psychiatry 2000; 68:679-680.
92. Kupiec T, Raj V: Fatal seizures due to potential herb-drug interactions with Ginkgo bi-loba. J Anal Toxicol 2005; 29:755-758.
93. Wiegman DJ, Brinkman K, Franssen EJ: Interaction of Ginkgo biloba with efavirenz. AIDS 2009;23: 1184-1185.
94. Beckert BW, Concannon MJ, Henry SL, Smith DS, Puckett CL: The effect of herbal medicines on platelet function: an in vivo experiment and review of the literature. Plast Reconstr Surg 2007; 120:2044-2050.
95. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-599.
96. Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC: Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med 2008; 14:715-721.
97. Lee YH, Lee BK, Choi YJ, Yoon IK, Chang BC, Gwak HS: Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. Int J Cardiol 2010; 145:275-276.
98. Janetzky K, Morreale AP: Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54: 692-693.
99. Shader RI, Greenblatt DJ: Bees, ginseng and MAOIs revisited. J Clin Psychopharmacol 1988; 8: 235.
100. Jones BD, Runikis AM: Interaction of ginseng with phenelzine. J Clin Psychophar-macol 1987; 7:201-202.
101. Bilgi N, Bell K, Ananthakrishnan AN, Atal-lah E: Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010; 44: 926-928.
102. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J: Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004; 141: 23-27.
103. Andrade AS, Hendrix C, Parsons TL, Ca-ballero B, Yuan CS, Flexner CW, Dobs AS, Brown TT: Pharmacokinetic and metabolic effects of American ginseng (Panax quin-quefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med 2008; 8:50.
104. Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS: Possible differential induction of phase 2 enzyme and antioxi-dant pathways by American ginseng, Panax quinquefolius. J Clin Pharmacol 2008; 48: 599-609.
105. Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S: Effect of golden-seal (Hydrastis canadensis) and kava ka-va (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2007; 35: 240-245.
106. Sandhu RS, Prescilla R P, Simonelli TM, Edwards DJ: Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 2003; 43:1283-1288.
107. Gurley BJ, Swain A, Hubbard MA, Harts-field F, Thaden J, Williams DK, Gentry WB, Tong Y: Supplementation with golden-seal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 2008; 83: 61-69.
108. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A: In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P4501A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77:415-426.
109. Taylor JR, Wilt VM: Probable antagonism of warfarin by green tea. Ann Pharmaco-ther 1999; 33:426-428.
110. Alemdaroglu NC, Dietz U, Wolffram S, Spahn-Langguth H, Langguth P: Influence of green and black tea on folic acid pharma-cokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm Drug Dispos 2008; 29:335-348.
111. Werba JP, Giroli M, Cavalca V, Nava MC, Tremoli E, Dal Bo L: The effect of green tea on simvastatin tolerability. Ann Intern Med 2008; 149:286-287.
112. Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts D: Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006; 15: 2473-2476.
113. Donovan JL, Chavin KD, Devane CL, Taylor RM, Wang JS, Ruan Y, Markowitz JS: Green tea (Camellia sinensis) extract does not alter cytochrome p4503A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32: 906-908.
114. Anke J, Ramzan I: Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J Ethno-pharmacol 2004; 93: 153-160.
115. Almeida JC, Grimsley EW: Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125: 940-941.
116. Schelosky L, Raffauf C, Jendroska K, Poewe W: Kava and dopamine antagonism. J Neu-rol Neurosurg Psychiatry 1995; 58: 639-640.
117. Rubin D, McGovern B, Kopelman RI: Back to basics. Am J Med 2006; 119:482-483.
118. Shon JH, Park JY, Kim MS. Cha IJ, Chun BH, Shin JG: Ef fect of licorice (rad ix glycyr-rhizae) on the pharmacokinetics and phar-macodynamics of midazolam in healthy subjects. Clin Pharmacol Ther 2001; 69:P78.
119. Li HY, Xu W, Su J, Zhang X, Hu LW, Zhang WD: In vitro and in vivo inhibitory effects of glycyrrhetinic acid on cytochrome P4503A activity. Pharmacology 2010; 86:287-292.
120. Tu JH, Hu DL, Dai LL, Sun Y, Fan L, Zhang M, Tan ZR, Chen Y, Li Z, Zhou HH: Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Xenobiotica 2010; 40: 393-399.
121. Homma M, Oka K, Ikeshima K, Takahashi N, Niitsuma T, Fukuda T, Itoh H: Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. J Pharm Pharmacol 1995; 47:687-692.
122. Chen MF, Shimada F, Kato H, Yano S, Kanaoka M: Effect of oral administration of glyc-yrrhizin on the pharmacokinetics of pred-nisolone. Endocrinol Jpn 1991; 38: 167-174.
123. Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR: Study on the influence of sily-marin pretreatment on metabolism and disposition of metronidazole. Arzneimit-telforschung 2004; 54:109-113.
124. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K: Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005; 61:1-7.
125. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G: Coad-ministration of milk thistle and indina-vir in healthy subjects. Pharmacotherapy 2003; 23: 866-870.
126. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J: Effect of milk thistle on the pharmacokinetics of in-dinavir in healthy volunteers. Pharmaco-therapy 2002; 22:551-556.
127. Leber HW, Knauff S: Influence of silyma-rin on drug metabolising enzymes in rat and man. Arzneimittelforschung 1976; 26: 1603-1605.
128. Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, Mengs U: The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 2007; 73: 1429-1435.
129. van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H: Effect of milk thistle (Sily-bum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005; 11: 7800-7806.
130. Deng JW, Shon JH, Shin HJ, Park SJ, Yeo CW, Zhou HH, Song IS, Shin JG: Effect of silymarin supplement on the pharmacoki-netics of rosuvastatin. Pharm Res 2008; 25: 1807-1814.
131. Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG: Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cy-tochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002; 72: 247-255.
132. Prasad GV, Wong T, Meliton G, Bhaloo S: Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 2002; 74: 1200-1201.
133. Kuncl RW: Agents and mechanisms of toxic myopathy. Curr Opin Neurol 2009; 22: 506-515.
134. Markowitz JS, Donovan JL, Devane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD: Multiple doses of saw palmetto (Serenoa re-pens) did not alter cytochrome P4502D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003; 74: 536-542.
135. Yue QY, Jansson K: Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc 2001; 49: 838.
136. Corrigan JJ Jr, Marcus FI: Coagulopathy associated with vitamin E ingestion. JAMA 1974; 230: 1300-1301.
137. Lu Y, Chen DF: Analysis of Schisandra chinensis and Schisandra sphenanthera. J Chromatogr A 2009; 1216: 1980-1990.
138. Jiang W, Wang X, Xu X, Kong L: Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients. Int J Clin Pharmacol Ther 2010; 48:224-229.
139. Xin HW, Wu XC, Li Q, Yu AR, Zhu M, Shen Y, Su D, Xiong L: Effects of Schisandra sphenanthera extract on the pharmacoki-netics of tacrolimus in healthy volunteers. Br J Clin Pharmacol 2007; 64:469-475.
140. Xin HW, Wu XC, Li Q, Yu AR, Xiong L: Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. Br J Clin Pharmacol 2009; 67:541-546.
141. Cambria-Kiely JA: Effect of soy milk on warfarin efficacy. Ann Pharmacother 2002; 36:1893-1896.
142. Wang G, Xiao CQ, Li Z, Guo D, Chen Y, Fan L, Qian RH, Peng XJ, Hu DL, Zhou HH: Effect of soy extract administration on losar-tan pharmacokinetics in healthy female volunteers. Ann Pharmacother 2009; 43: 1045-1049.
143. Borrelli F, Izzo AA: Herb-drug interactions with St John's wort (Hypericum perfora-tum): an update on clinical observations. AAPS J 2009; 11: 710-727.
144. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD: Ef fect of St John's wor t on drug metab ol ism by induction of cytochrome P4503A4 enzyme. JAMA 2003; 290:1500-1504.
145. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I: No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyper-forin St John's wort extract. Planta Med 2005; 71: 331-337.
146. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD: The effects of St John's wor t (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70:317-326.
147. Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH: The influence of St John's Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004; 44: 577-581.
148. Wenk M, Todesco L, Krähenbühl S: Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyl-transferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004; 57: 495-499.
149. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB: Coordinate induction of both cy-tochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003; 73: 41-50.
150. Roby CA, Dryer DA, Burstein AH: St John's wort: effect on CYP2D6 activity using dex-tromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001; 21: 530-532.
151. Xie R, Tan LH, Polasek EC, Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens DJ, Arakawa T, Knuth DW, Antal EJ: CYP3A and P-glycoprotein activity induction with St John's Wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005; 45: 352-356.
152. Mueller SC, Majcher-Peszynska J, Mund-kowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B: No clinically relevant CYP3A induction after St John's wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81-87.
153. Wang XD, Li JL, Su QB, Guan S, Chen J, Du J, He YW, Zeng J, Zhang JX, Chen X, Huang M, Zhou SF: Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P4503A4 enzyme. Br J Clin Pharmacol 2009; 67:255-261.
154. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH: St John's wort induces both cytochrome P4503A4-cata-lyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004; 75: 191-197.
155. Hafner V, Jäger M, Matthée AK, Ding R, Burhenne J, Haefeli WE, Mikus G: Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 2010; 87: 191-196.
156. Wang XD, Li JL, Su QB, Guan S, Chen J, Du J, He YW, Zeng J, Zhang JX, Chen X, Huang M, Zhou SF: Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P4503A4 enzyme. Br J Clin Pharmacol 2009; 67:255-261.
157. Imai H, Kotegawa T, Tsutsumi K, Morimo-to T, Eshima N, Nakano S, Ohashi K: The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol 2008; 65:701-707.
158. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I: Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76:330-340.
159. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC: The interaction bet ween St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74: 525-535.
160. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B: The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62: 29-36.
161. Mueller SC, Majcher-Peszynska J, Mund-kowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B: No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81-87.
162. Bon S, Hartmann K, Kubn M: Johannis-kraut: ein Enzyminduktor? Schweiz Apoth Ztg 1999; 16: 535-536.
163. Breidenbach T, Kliem V, Burg M, Rader-macher J, Hoffmann MW, Klempnauer J: Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Trans plantation 2000; 69:2229-2230.
164. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J: Drug interaction of St John's wort with cyclosporin. Lancet 2000; 355: 1912.
165. Roots I, Johne A, Mauer A: Arzneimittel-Interaktionen von Hypericum-Extract. Proc Germ Soc Pharmacol, Berlin, June 2000.
166. Rey JM, Walter G: Hypericum perforatum (St John's wort) in depression: pest or blessing? Med J Aust 1998; 169: 583-586.
167. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G: Acute heart transplant rejection due to Sa int John's wort. Lancet 2000; 355: 548-549.
168. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR: Drug interaction between St John's wort and cyclosporine. Ann Pharmacother 2000; 34: 1013-1016.
169. Mai I, Krüger H, Budde K, Johne A, Brock-möller J, Neumayer HH, Roots I: Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38:500-502.
170. Karliova M, Treichel U, Malagò M, Frilling A, Gerken G, Broelsch CE: Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33: 853-855.
171. Mandelbaum A, Pertzborn F, Martin-Facklam M, Wiesel M: Unexplained decrease of cyclosporin trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000; 15:1473-1474.
172. Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR: St John's wort: a hidden risk for transplant patients. Prog Tra nsplant 2001; 11: 116-120.
173. Ahmed SM, Banner NR, Dubrey SW: Low cyclosporin-A level due to Saint-John's-wort in heart transplant patients. J Heart Lung Transplant 2001; 20:795.
174. Beer AM, Ostermann T: St. John's wort: interaction with cyclosporine increases risk of rejection for the kidney transplant and raises daily cost of medication (in German). Med Klin (Munich) 2001; 96:480-483.
175. Moschella C, Jaber BL: Interaction between cyclosporine and Hypericum perforatum (St John's wort) after organ transplantation. Am J Kidney Dis 2001; 38:1105-1107.
176. Alscher DM, Klotz U: Drug interaction of herbal tea containing St John's wort with cyclosporine. Transpl Int 2003; 16: 543-544.
177. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM: Effects of St John's wort (Hy-pericum perforatum) on tacrolimus phar-macokinetics in healthy volunteers. J Clin Pharmacol 2004; 44: 89-94.
178. Mai I, Störmer E, Bauer S, Krüger H, Budde K, Roots I: Impact of St John's wort treatment on the pharmacokinetics of tacroli-mus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003; 18: 819-822.
179. Saraga M, Zullino DF: St John's Wort, cor-ticosteroids, cocaine, alcohol a first manic episode (in French). Praxis (Bern 1994) 2005; 94: 987-989.
180. Bell EC, Ravis WR, Chan HM, Lin YJ: Lack of pharmacokinetic interaction between St John's wort and prednisone. Ann Pharma-cother 2007; 41:1819-1824.
181. Caraci F, Crupi R, Drago F, Spina E: Metabolic drug interactions between antide-pressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab 2011; 12:570-577.
182. Howland RH: Update on St John's Wort. J Psychosoc Nurs Ment Health Serv 2010; 48: 20-24.
183. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J: Interaction of St John's wort with low-dose oral contraceptive therapy: a ra ndomi zed controlled trial. Br J Clin Pharmacol 2003; 56: 683-690.
184. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL: Interaction of St John's wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005; 71: 402-408.
185. Will-Shahab L, Bauer S, Kunter U, Roots I, Brattström A: St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol 2009; 65:287-294.
186. Schwarz UI, Büschel B, Kirch W: Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55:112-113.
187. Etogo-Asse F, Boemer F, Sempoux C, Geu-bel A: Acute hepatitis with prolonged cho-lestasis and disappearance of interlobular bile ducts following tibolone and Hyperi-cum perforatum (St John's wort). Case of drug interaction? Acta Gastroenterol Belg 2008; 71: 36-38.
188. Wang PH, Cheng MH, Chao HT, Chao KC: Effects of tibolone on the breast of post-menopausal women. Taiwan J Obstet Gy-necol 2007; 46:121-126.
189. Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, Langheinrich M, Hübner WD: Interaction of St John's wort extract with phenprocoumon. Eur J Clin Pharmacol 1999; 55:A22.
190. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I: Pharmacokinetic interaction of digoxin with an herbal ext ract from St John's wort (Hypericum perfo-ratum). Clin Pharmacol Ther 1999; 66:338-345.
191. Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B: Effect of St John's wort dose and pre parations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004; 75: 546-557.
192. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A: Different effects of St John's wort on the pharmacokinetics of simva-statin and pravastatin. Clin Pharmacol Ther 2001; 70: 518-524.
193. Andrén L, Andreasson A, Eggertsen R: Interaction between a commercially available St John's wort product (Movina) and ator-vastatin in patients with hypercholesterol-emia. Eur J Clin Pharmacol 2007; 63:913-916.
194. Gordon RY, Becker DJ, Rader DJ: Reduced efficacy of rosuvastatin by St John's wort. Am J Med 2009; 122:e1-e2.
195. Portolés A, Terleira A, Calvo A, Martínez I, Resplandy G: Effects of Hypericum Perfora tum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharma-cokinetic interaction clinical trial. J Clin Pharmacol 2006; 46:1188-1194.
196. Tannergren C, Engman H, Knutson L, He-deland M, Bondesson U, Lennernäs H: St John's wort decreases the bioavailability of R-and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75: 298-309.
197. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W: Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 2007; 81: 669-678.
198. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J: Indinavir concentrations and St John's wort. Lancet 2000; 355: 547-548.
199. de Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH: Drug interaction between St John's wort and nevirapine. AIDS 2001; 15: 420-421.
200. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A: Effects of St John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-1249.
201. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ: Effect of St John's wort on imatinib mesylate pharmacokinet-ics. Clin Pharmacol Ther 2004; 76:323-329.
202. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ: The influence of St John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Phar-macotherapy 2004; 24:1508-1514.
203. Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A: Drug interaction between St John's Wort and qua zepam. Br J Clin Pharmacol 2004; 58: 403-410.
204. Hojo Y, Echizenya M, Ohkubo T, Shimizu T: Drug interaction between St John's wort and zolpidem in healthy subjects. J Clin Pharm Ther 2011; 36: 711-715.
205. Dannawi M: Possible serotonin syndrome after combination of buspirone and St John's Wort. J Psychopharmacol 2002; 16: 401.
206. Lantz MS, Buchalter E, Giambanco V: St John's wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12:7-10.
207. Gordon JB: SSRIs and St John's wort: possible toxicity? Am Fam Physician 1998; 57: 950.
208. Bryant SM, Kolodchak J: Serotonin syndrome resulting from an herbal detox cocktail. Am J Emerg Med 2004; 22: 625-626.
209. Barbenel DM, Yusufi B, O'Shea D, Bench CJ: Mania in a patient receiving testosterone replacement postorchidectomy taking St John's wort and sertraline. J Psychophar-macol 2000; 14: 84-86.
210. Johne A, Schmider J, Brockmöller J, Stadel-mann AM, Störmer E, Bauer S, Scholler G, Langheinrich M, Roots I: Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22:46-54.
211. Crowe S, McKeating K: Delayed emergence and St John's wort. Anesthesiology 2002; 96: 1025-1027.
212. Irefin S, Sprung J: A possible cause of cardiovascular collapse during anesthesia: long-term use of St John's Wort. J Clin Anesth 2000; 12:498-499.
213. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G: Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacoki-netics. Clin Pharmacol Ther 2005; 78:25-33.
214. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W: Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000; 68:605-612.
215. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH: Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-1979.
216. Eich-Höchli D, Oppliger R, Golay KP, Bau-mann P, Eap CB: Methadone maintenance treatment and St John's Wort-a case report. Pharmacopsychiatry 2003; 36: 35-37.
217. Milton JC, Abdulla A: Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John's wort. Br J Clin Pharmacol 2007; 64: 717-718.
218. Lei HP, Yu XY, Xie HT, Li HH, Fan L, Dai LL, Chen Y, Zhou HH: Effect of St John's wort supplementation on the pharmacoki-netics of bupropion in healthy male Chinese volunteers. Xenobiotica 2010; 40:275-281.
219. Nebel A, Schneider BJ, Baker RK, Kroll DJ: Potential metabolic interaction between St John's wort and theophylline. Ann Phar-macother 1999; 33:502.
220. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S: Effect of St John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004; 44: 95-101.
221. Bonetto N, Santelli L, Battistin L, Cagnin A: Serotonin syndrome and rhabdomyoly-sis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia 2007; 27:1421-1423.
222. Carrasco MC, Vallejo JR, Pardo-de-Santa-yana M, Peral D, Martín MA, Altimiras J: Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phy tother Res 2009; 23: 1795-1796.
223. Khawaja IS, Marotta RF, Lippmann S: Herbal medicines as a factor in delirium. Psychiatr Ser v 1999; 50: 969-970.
224. Deahl M: Betel nut-induced extrapyrami-dal syndrome: an unusual drug interaction. Mov Disord 1989; 4:330-332.
225. Ohkawa S, Yoneda Y, Ohsumi Y, Tabuchi M: Warfarin therapy and chlorella (in Japanese). Rinsho Shinkeigaku 1995; 35: 806-807.
226. Lambert JP, Cormier J: Potential interaction between warfarin and boldo-fenu-greek. Pharmacotherapy 2001; 21: 509-512.
227. Holman CP, Bell AFJ: A trial of evening primrose oil in the treatment of chronic schizophrenia. J Orthomol Psychiatry 1983; 12:302-304.
228. Hanselin MR, Vande Griend JP, Linnebur SA: INR elevation with maitake extract in combination with warfarin. Ann Pharma-cot her 2010; 44: 223-224.
229. Gutsch J: On the state of therapy of chronic myeloid leukemia in adults with the mistletoe preparation Helixor (in German). Ärz-tezeitschrift für Naturheilverfahren 1982; 23: 523-544.
230. Sobieraj DM, Freyer CW: Probable hypo-glycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus. Ann Pharmacot her 2010; 44: 1334-1337.
231. Leung H, Hung A, Hui AC, Chan TY: Warfarin overdose due to the possible effects of Lycium barbarum L. Food Chem Toxicol 2008; 46:1860-1862.
232. Lam AY, Elmer GW, Mohutsky MA: Possible interaction between warfarin and Ly-cium barbar um L. Ann Pharmacother 2001; 35: 1199-1201.
233. Mahmoud BM, Ali HM, Homeida MM, Bennett JL: Significant reduction in chloro-quine bioavailability following coadminis-tration with the Sudanese beverages Ara-daib, Karkadi and Lemon. J Antimicrob Chemother 1994; 33:1005-1009.
234. Kolawole JA, Maduenyi A: Effect of zobo drink (Hibiscus sabdariffa water extract) on the pharmacokinetics of acetaminophen in human volunteers. Eur J Drug Metab Pharmacokinet 2004; 29:25-29.
235. Richter WO, Jacob BG, Schwandt P: Interaction between fibre and lovastatin. Lancet 1991; 338:706.
236. Gin H, Orgerie MB, Aubertin J: The influence of Guar gum on absorption of metfor-min from the gut in healthy volunteers. Horm Metab Res 1989; 21: 81-83.
237. Eltayeb IB, Awad AI, Elderbi MA, Shadad SA: Effect of gum arabic on the absorption of a single oral dose of amoxicillin in healthy Sudanese volunteers. J Antimicrob Chemother 2004; 54:577-578.
238. Dalvi SS, Nayak VK, Pohujani SM, Desai NK, Kshirsagar NA, Gupta KC: Effect of gugulipid on bioavailability of diltiazem and propranolol. J Assoc Physicians India 1994; 42:454-455.
239. Huupponen R, Seppälä P, Iisalo E: Effect of guar gum, a fibre preparation, on digoxin and penicillin absorption in man. Eur J Clin Pharmacol 1984; 26: 279-281.
240. Al Faraj S: Antagonism of the anticoagulant effect of warfarinc aused by the use of Com-miphora molmol as a herbal medication: a case report. Ann Trop Med Parasitol 2005; 99: 219-220.
241. Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton JL, Annesley T, Aaron-son KD, Bleske BE: Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003; 43:637-642.
242. De Smet PA, Floor-Schreudering A, Bouvy ML, Wensing M: Clinical risk management of interactions between natural products and drugs. Curr Drug Metab 2008; 9: 1055-1062.
243. González-Stuart A: Herbal product use by older adults. Maturitas 2011; 68:52-55.
244. Ueng YF, Chen CC, Tsai CC, Soucek P: Differential inductive profiles of hepatic cyto-chrome P450s by the extracts of Sophora flavescens in male and female C57BL/6JNarl mice. J Ethnopharmacol 2009; 126:437-446.
245. Bush TM, Rayburn KS, Holloway SW, San-chez-Yamamoto DS, Allen BL, Lam T, So BK, Tran de H, Greyber ER, Kantor S, Roth LW: Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Altern Ther Hea lth Med 2007; 13: 30-35.
246. Harrigan JT: Patient disclosure of the use of complementary and alternative medicine to their obstetrician/gynaecologist. J Ob-stet Gy naecol 2011; 31: 59-61.
247. Wanwimolruk S, Wong K, Wanwimolruk P: Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4. Drug Metabol Drug Interact 2009; 24:17-35.
248. Capasso R, Izzo AA, Pinto L, Bifulco T, Vitobello C, Mascolo N: Phytotherapy and quality of herbal medicines. Fitoterapia 2000; 71(suppl 1):S58-S65.
249. King AR, Russett FS, Generali JA, Grauer DW: Evaluation and implications of natural product use in preoperative patients: a retrospective review. BMC Complement Al-tern Med 2009; 9: 38.